Christophe Weber, Takeda CEO (Shoko Takayasu/Bloomberg via Getty Images)
As part of broader gene therapy ambitions, Takeda links up again with a small Chicago biotech
Takeda is inking gene therapy deals left and right. This time, it’s partnering for a second time with Chicago-based protein maker Evozyne.
After lining up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
